Onconic Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Onconic Therapeutics is a South Korean drug-development company focused on treatments for acid-related digestive diseases and cancer.
Its lead approved product, Zaquvo, is an oral tablet that blocks stomach-acid production through a mechanism called P-CAB (potassium-competitive acid blocker), offering faster onset and more flexible dosing than the widely used older class of acid-suppression drugs known as PPIs. Listed on KOSDAQ, Korea's tech and small-cap board, the company concentrates its research on small-molecule drugs, chemically synthesised compounds that are generally less costly to develop and manufacture than biological medicines.
Summary is AI-generated and may contain errors · figures from DART filings
Zaquvo holds domestic new-drug approval in Korea as the thirty-seventh domestically developed new drug, a government-tracked designation that reflects the country's pharmaceutical innovation pipeline.
Onconic Therapeutics in five facts
What does Onconic Therapeutics do?
Onconic Therapeutics is a South Korean drug-development company focused on treatments for acid-related digestive diseases and cancer.
Where is Onconic Therapeutics listed and in which sector?
Onconic Therapeutics (Korean name: 온코닉테라퓨틱스) trades under KRX code 476060 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Onconic Therapeutics?
Its market capitalisation was US$471.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Onconic Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, Onconic Therapeutics reported revenue of US$40.3M, operating profit of US$9.5M and net income of US$11.9M, per its annual report on DART (data retrieved from DART on 2026-06-04). Revenue was up 259.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Shareholder register closure / record date setOct 16
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 16
- Proxy solicitation reference documentOct 16
- Notice of general shareholders' meetingOct 16
- Appointment/dismissal/resignation of an independent directorSep 3
- DisclosureSep 2
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Onconic Therapeutics updated its previously filed separate results for FY2025: revenue of US$36.1M (+259.8% year on year), operating profit of US$8.53M (from a loss a year earlier) and net income of US$10.7M (from a loss a year earlier).
Earnings · Mar 6 · 3 versions